RECORD // Company

Sarepta Therapeutics, Inc.

Formerly: Sarepta Therapeutics, Inc.; AVI BIOPHARMA INC; ANTIVIRALS INC

Built 2026-11-21T11:33:59Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (13)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Sarepta Therapeutics, Inc. · Ctgov · same registered legal name as 'Sarepta Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Sarepta Therapeutics, Inc. · East licences · same registered legal name as 'Sarepta Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Sarepta Therapeutics, Inc. · East licences · same registered legal name as 'Sarepta Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS · Epa echo · exact name match to 'Sarepta Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS · Epa echo · exact name match to 'Sarepta Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS · Epa echo · exact name match to 'Sarepta Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS · Epa echo · exact name match to 'Sarepta Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS · Epa echo · exact name match to 'Sarepta Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS · Epa echo · exact name match to 'Sarepta Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS · Epa echo · exact name match to 'Sarepta Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS · Epa rcra · exact name match to 'Sarepta Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS, INC. · USAspending · same registered legal name as 'Sarepta Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • SAREPTA THERAPEUTICS, INC. · USAspending · same registered legal name as 'Sarepta Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

11 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001193125-26-449721

ItemValuePeriodFormFiledAccessionReport
Revenue$381,351,0003 months ended 2026-09-3010-Q2026-11-050001193125-26-4497212026-11-21 11:33 UTCReport an error
Net income (loss)$-28,461,0003 months ended 2026-09-3010-Q2026-11-050001193125-26-4497212026-11-21 11:33 UTCReport an error
Interest expense$21,616,0003 months ended 2026-09-3010-Q2026-11-050001193125-26-4497212026-11-21 11:33 UTCReport an error
Cash and cash equivalents$472,760,000at 2026-09-3010-Q2026-11-050001193125-26-4497212026-11-21 11:33 UTCReport an error
Contract liabilities, current$104,887,000at 2026-09-3010-Q2026-11-050001193125-26-4497212026-11-21 11:33 UTCReport an error
Contract liabilities, noncurrent$83,910,000at 2026-09-3010-Q2026-11-050001193125-26-4497212026-11-21 11:33 UTCReport an error
Debt due in the next 12 months (from an earlier report)$41,597,000at 2025-12-3110-K2026-03-020001193125-26-0841442026-11-21 11:33 UTCReport an error
Debt due in year 2 (from an earlier report)$204,144,000at 2025-12-3110-K2026-03-020001193125-26-0841442026-11-21 11:33 UTCReport an error
Debt due in year 3 (from an earlier report)$43,553,000at 2025-12-3110-K2026-03-020001193125-26-0841442026-11-21 11:33 UTCReport an error
Debt due in year 4 (from an earlier report)$43,553,000at 2025-12-3110-K2026-03-020001193125-26-0841442026-11-21 11:33 UTCReport an error
Debt due in year 5 (from an earlier report)$937,068,000at 2025-12-3110-K2026-03-020001193125-26-0841442026-11-21 11:33 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0000873303
Ticker
SRPT
EIN
930797222
CUSIP
803607100
Record ID
sx:sec:0000873303

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

42 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-13SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-13SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
State of incorporationDE2026-11-13SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
Fiscal year end (MMDD)12312026-11-13SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
Business address215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 021422026-11-13SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
ExchangesNasdaq2026-11-13SEC EDGAR company profile2026-11-21 11:33 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$2,198,237,0002025-12-3110-K, XBRL Revenues2026-11-21 11:33 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-713,410,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:33 UTCReport an error
Total assets (at 2025-12-31)$3,349,703,0002025-12-3110-K, XBRL Assets2026-11-21 11:33 UTCReport an error
Stockholders' equity (at 2025-12-31)$1,140,622,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:33 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$801,282,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:33 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-205,479,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:33 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$101,972,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:33 UTCReport an error
Long-term debt (at 2025-12-31)$828,974,0002025-12-3110-K, XBRL LongTermDebt2026-11-21 11:33 UTCReport an error
Operating lease liabilities (at 2025-12-31)$210,574,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:33 UTCReport an error
Form D total offering amount (D filed 2020-02-28)$399,999,9802020-02-28D2026-11-21 11:33 UTCReport an error
Form D total amount sold (D filed 2020-02-28)$399,999,9802020-02-28D2026-11-21 11:33 UTCReport an error
Form D industry groupBiotechnology2020-02-28D2026-11-21 11:33 UTCReport an error
Form D revenue rangeDecline to Disclose2020-02-28D2026-11-21 11:33 UTCReport an error
Form D date of first sale2020-02-142020-02-28D2026-11-21 11:33 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-05)On November 5, 2026, Sarepta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a…2026-11-05SEC EDGAR 8-K 0001193125-26-449822 (text as filed, excerpt)2026-11-21 11:33 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-09-23)On September 23, 2026 (the “Effective Date”), Sarepta Therapeutics, Inc. (the “Company”), Sarepta Therapeutics Three, LLC (“Sarepta Three” and, together with the Company, “Sarepta”), REGENXBIO Inc. (“REGENXBIO”), the Trustees of the University of Pennsylvania (“UPenn”) and Catalent, Inc. (“Catalent”) entered into a settlement agreement (the “Settlement Agreement”) regarding, among other matters, the resolution of pending patent infringement litigations and an appeal from inter partes review proceedings relating to U.S. Patent No. 11,680,274 (the “‘274 Patent”) and U.S. Patent No. 10,526,617 (the “‘617 Patent”) (collectively, the “Litigations”). As disclosed in the Company’s Quarterly Report…2026-09-23SEC EDGAR 8-K 0001193125-26-399416 (text as filed, excerpt)2026-11-21 11:33 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-05)On August 5, 2026, Sarepta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.2026-08-05SEC EDGAR 8-K 0001193125-26-335056 (text as filed, excerpt)2026-11-21 11:33 UTCReport an error
Employer name (as filed)Sarepta Therapeutics, Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Certified LCAs32026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Certified LCAs later withdrawn02026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Total worker positions on certified LCAs32026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Top job titles (title, LCA count)QC Analyst (1); Director, Quality Control (1); Senior Scientist, Discovery Chemistry (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Wage offered, annualized (n, min, median, max)median $131,000 (range $91,978-$191,000, 3 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Worksite statesMA2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:33 UTCReport an error
Plan (pension, plan no. 001)SAREPTA THERAPEUTICS, INC. 401(K) PLAN: 1,489 participants, assets $224,503,7222025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:33 UTCReport an error
Plan (welfare, plan no. 501)SAREPTA THERAPEUTICS, INC. EMPLOYEE BENEFIT PLAN: 940 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:33 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$341,339,3982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #2 (13F as filed): STATE STREET CORP$160,222,1372026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$150,543,1362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #4 (13F as filed): TWO SIGMA INVESTMENTS, LP$82,639,2682026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$82,513,8372026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #6 (13F as filed): FIRST TRUST ADVISORS LP$78,456,0862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #7 (13F as filed): AQR CAPITAL MANAGEMENT LLC$76,867,4922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #8 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$49,818,7962026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #9 (13F as filed): Erste Asset Management GmbH$45,513,6252026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error
Largest institutional holder #10 (13F as filed): MARSHALL WACE, LLP$39,642,2162026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:33 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.